Milestone Pharmaceuticals (MIST) Expected to Announce Earnings on Wednesday

Milestone Pharmaceuticals (NASDAQ:MIST) is anticipated to announce its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect Milestone Pharmaceuticals to post earnings of ($0.18) per share and revenue of $0.8170 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 12, 2026 at 8:30 AM ET.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its earnings results on Wednesday, May 13th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.26). The firm had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $30.11 million. On average, analysts expect Milestone Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Milestone Pharmaceuticals Price Performance

Shares of Milestone Pharmaceuticals stock opened at $1.18 on Wednesday. The company has a quick ratio of 9.09, a current ratio of 9.18 and a debt-to-equity ratio of 1.61. Milestone Pharmaceuticals has a twelve month low of $1.00 and a twelve month high of $3.06. The business has a 50-day moving average price of $1.26 and a 200 day moving average price of $1.56. The firm has a market cap of $146.29 million, a PE ratio of -1.73 and a beta of 0.98.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in MIST. Bank of America Corp DE boosted its stake in Milestone Pharmaceuticals by 200,550.0% during the 3rd quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after purchasing an additional 16,044 shares during the last quarter. Cetera Investment Advisers acquired a new stake in shares of Milestone Pharmaceuticals in the fourth quarter valued at about $42,000. Invesco Ltd. purchased a new position in shares of Milestone Pharmaceuticals in the fourth quarter worth about $44,000. Creative Planning lifted its stake in shares of Milestone Pharmaceuticals by 74.6% in the second quarter. Creative Planning now owns 23,410 shares of the company’s stock worth $45,000 after buying an additional 10,000 shares in the last quarter. Finally, Raymond James Financial Inc. boosted its position in Milestone Pharmaceuticals by 30.1% during the second quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock worth $84,000 after acquiring an additional 10,000 shares during the last quarter. 86.18% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a report on Tuesday, July 14th. Wells Fargo & Company reduced their target price on Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating for the company in a research note on Thursday, May 14th. Wall Street Zen lowered Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Sunday, May 17th. Zacks Research raised shares of Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Finally, Raymond James Financial started coverage on shares of Milestone Pharmaceuticals in a research report on Friday, April 10th. They set a “strong-buy” rating and a $6.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $7.25.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.